clinical trial · NCT07516093
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
B-cell LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaNX-5948Pirtobrutinib
brief summary
The study will evaluate the efficacy and safety of NX-5948 (bexobrutideg) versus pirtobrutinib in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who are relapsed or refractory to prior covalent Bruton tyrosine kinase inhibitor (cBTKi) treatment.
started
Jun 1, 2026
primary completion
Oct 1, 2029
completion
Jun 1, 2032
last updated
Apr 8, 2026
official title
A Phase 3, Randomized, Open-label, Multicenter Study of NX-5948 Versus Pirtobrutinib in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol